Is BlackRock a Buy, Sell or Hold
With a large suite of ETF offerings as well as…
Sell
43
IPHA Quote, Financials, Valuation and Earnings
Last price:
$1.99
Seasonality move
:
-11.27%
Day range:
$1.96 - $1.99
52-week range:
$1.29 - $3.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.78x
P/B ratio:
17.96x
Volume:
4.3K
Avg. volume:
22.3K
1-year change:
-18.26%
Market cap:
$165.1M
Revenue:
$13.7M
EPS (TTM):
-$0.45
Analysts' Opinion
-
Consensus RatingInnate Pharma SA has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.02, Innate Pharma SA has an estimated upside of 307.11% from its current price of $1.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.56 representing 100% downside risk from its current price of $1.97.
Fair Value
-
According to the consensus of 2 analysts, Innate Pharma SA has 307.11% upside to fair value with a price target of $8.02 per share.
IPHA vs. S&P 500
-
Over the past 5 trading days, Innate Pharma SA has overperformed the S&P 500 by 9.91% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Innate Pharma SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innate Pharma SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Innate Pharma SA reported revenues of --.
Earnings Growth
-
Innate Pharma SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Innate Pharma SA reported earnings per share of --.
Enterprise value:
113.3M
EV / Invested capital:
--
Price / LTM sales:
11.78x
EV / EBIT:
0.37x
EV / Revenue:
8.36x
PEG ratio (5yr expected):
0.03x
EV / Free cash flow:
-14.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
0.32x
Gross Profit (TTM):
--
Return On Assets:
-18.89%
Net Income Margin (TTM):
-137.02%
Return On Equity:
-72.79%
Return On Invested Capital:
-39.78%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-04-30 | 2020-04-30 | 2021-04-30 | 2020-04-30 | 2021-04-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | $262.4M | $261.1M | |
| Gross Profit | -- | -- | -- | $98.7M | $100.7M | |
| Operating Income | -- | -- | -- | $46.3M | $51.4M | |
| EBITDA | -- | -- | -- | $55.1M | $59M | |
| Diluted EPS | -- | -- | -- | $0.38 | $0.42 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $213.3M | $156.5M | $150M | $163.6M | $89.2M | |
| Total Assets | $378.1M | $302.9M | $222.9M | $203.6M | $115.6M | |
| Current Liabilities | $55.9M | $90.4M | $44.3M | $43.8M | $34.3M | |
| Total Liabilities | $186.3M | $181.2M | $164.8M | $146.2M | $106.4M | |
| Total Equity | $191.8M | $121.6M | $58.1M | $57.4M | $9.2M | |
| Total Debt | $19.1M | $46.9M | $44M | $43.2M | $32.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2020-03-31 | 2021-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | $22.5B | $4B | |
| Cash From Investing | -- | -- | -- | $5B | $14.2M | |
| Cash From Financing | -- | -- | -- | $492.2M | -$789K | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
IPHA
Sector
Market Cap
$165.1M
$35M
Price % of 52-Week High
56.11%
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-18.26%
-41.61%
Beta (5-Year)
0.334
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.88
200-day SMA
Sell
Level
$2.00
Bollinger Bands (100)
Buy
Level
1.66 - 2.14
Chaikin Money Flow
Sell
Level
-40.4M
20-day SMA
Buy
Level
$1.88
Relative Strength Index (RSI14)
Buy
Level
53.31
ADX Line
Buy
Level
10.78
Williams %R
Neutral
Level
-46.2428
50-day SMA
Sell
Level
$1.99
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
163.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.7184)
Sell
CA Score
(Annual)
Level (-3.1614)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.6646)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Stock Forecast FAQ
In the current month, IPHA has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IPHA average analyst price target in the past 3 months is $8.02.
-
Where Will Innate Pharma SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innate Pharma SA share price will rise to $8.02 per share over the next 12 months.
-
What Do Analysts Say About Innate Pharma SA?
Analysts are divided on their view about Innate Pharma SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innate Pharma SA is a Sell and believe this share price will drop from its current level to $2.56.
-
What Is Innate Pharma SA's Price Target?
The price target for Innate Pharma SA over the next 1-year time period is forecast to be $8.02 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IPHA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innate Pharma SA is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of IPHA?
You can purchase shares of Innate Pharma SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innate Pharma SA shares.
-
What Is The Innate Pharma SA Share Price Today?
Innate Pharma SA was last trading at $1.99 per share. This represents the most recent stock quote for Innate Pharma SA. Yesterday, Innate Pharma SA closed at $1.97 per share.
-
How To Buy Innate Pharma SA Stock Online?
In order to purchase Innate Pharma SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy, Sell or Hold?
Uber (NYSE:UBER) has been through quite a ride over the…
Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 18
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 18
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 18
Global Payments [GPN] is down 17.44% over the past day.
